This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why
by Zacks Equity Research
CRVS stock surges 209% in a month after positive cohort 4 phase I data show durable eczema responses for soquelitinib.
REGNPositive Net Change ALKSPositive Net Change CRVSNegative Net Change KRYSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Murphy USA (MUSA) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
MUSANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?
by Ahan Chakraborty
NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded obesity drug race.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?
by Ekta Bagri
Keros Therapeutics advances KER-065 toward DMD trials, trims costs, and extends its cash runway as investors weigh it against Dyne???s deeper pipeline
DYNPositive Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is KROS' KER-065 the Next Breakthrough in DMD Space?
by Ekta Bagri
KROS is advancing KER-065 for Duchenne muscular dystrophy, with orphan drug status and a phase II trial planned for early 2026.
SRPTNegative Net Change PTCTNegative Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q4 Results?
by Ahan Chakraborty
Novo Nordisk's Q4 results hinge on Ozempic and Wegovy sales as demand growth slows amid guidance cuts due to intense rivalry and compounded drug headwinds.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
USA Compression Partners (USAC)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
USACPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Nicolet Bankshares (NIC)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
NICNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings
by Ahan Chakraborty
LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens beyond GLP-1s.
AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
JANX Enters Global Oncology Collaboration With BMY, Stock Rises
by Zacks Equity Research
Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.
BMYPositive Net Change FOLDNo Net Change KROSNegative Net Change JANXPositive Net Change
biotechnology biotechs medical pharmaceuticals